Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5267683 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RO5267683 | DRUG | Multiple ascending doses |
| placebo | DRUG | Multiple ascending doses |
Inclusion Criteria: * Healthy male and female subjects, 18 to 45 years of age, * Body mass index (BMI) 18 to 30 kg/m2 inclusive, and a minimum weight of 50 kg at screening * Female subjects must be surgically sterile or post-menopausal * Male subjects must use a barrier method of contraception for ...
RO5267683 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The only completed trial evaluated the drug in healthy subjects to assess its safety and tolerability.
RO5267683 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company sponsored a Phase 1 study of the drug in healthy volunteers.
RO5267683 is in Phase 1 clinical development. The single trial listed for the drug is a Phase 1 study that has been completed. The drug remains investigational and has not been approved by regulatory authorities.
RO5267683 has one completed clinical trial, NCT01398241, titled 'A Study of RO5267683 in Healthy Subjects'. This Phase 1 study enrolled 38 participants in France and was placebo-controlled, randomized, and double-blind.
RO5267683 is not FDA approved. It is an investigational drug that has only been studied in a Phase 1 clinical trial in healthy volunteers. The trial is completed, but the drug has not progressed to later-stage studies or received marketing approval.